Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part (SAD and MAD) Study to Assess the Safety, Tolerability, and Pharmacokinetics of ARN-75039 When Administered by the Oral Route in Healthy Adult Subjects.

NCT05735249 is registered in ClinicalTrials.gov with Arisan Therapeutics, Inc. as lead sponsor.

NCT NCT05735249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05735249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part (SAD and MAD) Study to Assess the Safety, Tolerability, and Pharmacokinetics of ARN-75039 When Administered by the Oral Route in Healthy Adult Subjects.
Lead sponsor
Arisan Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 23, 2023
Completion date
March 28, 2025
Enrollment
94 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adult participants